AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics
UK-based AstraZeneca plc (AZ, NASDAQ: AZN) is reportedly in negotiations with Summit Therapeutics, the US...
Multi-specific antibodies
Akeso Biopharma Initiates Phase Ia Clinical Study for Trop2/Nectin4 Bispecific ADC AK146D1
China-based Akeso Biopharma (HKG: 9926) announced the initiation of a Phase Ia clinical study for...
GenScript Receives $213.8M Payment from LaNova for PD-1 Antibody License
China-based GenScript Biotech Corporation (HKG: 1548) announced that it has received a payment of USD...
Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...
Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager
China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...
Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE
China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...
Genrix Bio Partners with Cullinan Therapeutics for GR1803 License
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...
Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...
Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs...
Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting
China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...
Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from...
ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc...
3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC
China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...
Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC
China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...
Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial
China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...
CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors
Zhejiang-based Zhejiang Shimai Pharmaceutical Co.，Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...
Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...